7:51 AM ET
8-K
Clinical Trial Data
Xencor Clinical Trial Data
Xencor announced updated Phase 1 clinical trial results for XmAb819, an ENPP3 x CD3 bispecific T-cell engager, in patients with advanced clear cell renal cell carcinoma (ccRCC). The company also provided a cash runway update, expecting current resources to fund operations into 2029, and plans to start a potential registration-enabling study for XmAb819 in 2027.